Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2017/V14/I6/381

[1] 冯伟,刘晖. 肺栓塞抗凝治疗新进展[J]. 临床肺科杂志,2015,20(1):135-137.
[2] 李艳霞,张中和. 抗凝在肺栓塞治疗中的地位及方法[J]. 中国实用外科杂志,2010,30(12):999-1001.
[3] 汪铮,陈孝谦,李秀. 肺栓塞患者危险因素及临床特征分析[J]. 临床肺科杂志,2013,18(2):255-257.
[4] 刘玉珍,张震宇,郭淑丽,等. 妇科盆腔手术后下肢深静脉血栓形成的临床研究[J]. 中华妇产科杂志,2006,41(2):107-110.
[5] 李瑛. 口服避孕药不良反应的有关问题[J]. 中国计划生育和妇产科,2012,4(3):5-9.
[6] 杜文民,王永铭,程能能. 药品不良反应的判定与其研究方法[J]. 中国药物警戒,2005,2(1):11-13，28.
[7] 元凤霞. 炔雌醇环丙孕酮片联合散结镇痛胶囊治疗子宫腺肌病的疗效观察[J]. 现代药物与临床,2014,29(6):668-671.
[8] 樊鹏利,苏远,伍三兰. 炔雌醇环丙孕酮致急性大面积肺栓塞1例[J]. 中国医院药学杂志,2015,35(19):1801-1802.
[9] 冯艳,丁辉,陈如华. 口服避孕药致肺血栓栓塞症2例及文献复习[J]. 中国新药与临床杂志,2013,32(3):248-250.
[10] 李坚. 使用口服避孕药的利与弊[J]. 中国实用妇科与产科杂志,2009,25(10):742-745.
[11] 李丽华,赵祎镭,吴兴繁. 炔雌醇环丙孕酮致静脉血栓1例[J]. 药物流行病学杂志,2008,17(4):253.
[12] Chen C H, Chin H Y, Chen H H, et al. Pills-related severe adverse events: A case report in Taiwan[J]. Taiwan J Obstet Gynecol，2016.55(4):588-590.
[13] Sharmila V, Babu T A. Oral contraceptive pills induced hemichorea in an adolescent female with polycystic ovarian disease[J]. Indian J Pharmacol，2015 ，47(2):232-233.
[14] Kromm J, Jeerakathil T. Cyproterone acetate-ethinyl estradiol use in a 23-year-old woman with stroke[J]. CMAJ，2014 ，186(9):690-693.
[15] 杨兴华,崔歆. 口服避孕药与静脉血栓栓塞[J]. 药物不良反应杂志,2010,12(5):329-332.
[16] 古忆,卢新政. 2011美国大面积肺栓塞、深静脉血栓形成及慢性血栓栓塞性肺动脉高压治疗指南解读[J]. 心血管病学进展,2012,33(2):164-167.
[17] 李艳霞,张中和. 肺栓塞的治疗[J]. 中国实用内科杂志,2010,30(4):303-306.
[18] 汪铮,陈孝谦,李秀. 肺栓塞患者危险因素及临床特征分析[J]. 临床肺科杂志,2013,18(2):255-257.
[19] 姜蓉,刘锦铭. 2014欧洲心脏病学会急性肺栓塞诊断及管理指南解读[J]. 世界临床药物,2016,37(7):446-452.
[20] 彭宁,高奇. 以晕厥为首发症状的3例肺栓塞患者误诊分析[J]. 重庆医学,2016,45(1):142-143.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.